GORECKI, Lukas, Anna MISIACHNA, Jiří DAMBORSKÝ, Rafael DOLEZAL, Jan KORABECNY, Lada CEJKOVA, Kristina HAKENOVA, Marketa CHVOJKOVA, Jana KARASOVA ZDAROVA, Lukas PRCHAL, Martin NOVAK, Marharyta KOLCHEVA, Stepan KORTUS, Karel VALES, Martin HORAK a Ondřej SOUKUP. Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-D-Aspartate receptors. European Journal of Medicinal Chemistry. PARIS: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, roč. 219, July 2021, s. 1-16. ISSN 0223-5234. Dostupné z: https://dx.doi.org/10.1016/j.ejmech.2021.113434.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Structure-activity relationships of dually-acting acetylcholinesterase inhibitors derived from tacrine on N-methyl-D-Aspartate receptors
Autoři GORECKI, Lukas (203 Česká republika), Anna MISIACHNA (203 Česká republika), Jiří DAMBORSKÝ (203 Česká republika, garant, domácí), Rafael DOLEZAL (203 Česká republika), Jan KORABECNY (203 Česká republika), Lada CEJKOVA (203 Česká republika), Kristina HAKENOVA (203 Česká republika), Marketa CHVOJKOVA (203 Česká republika), Jana KARASOVA ZDAROVA (203 Česká republika), Lukas PRCHAL (203 Česká republika), Martin NOVAK (203 Česká republika), Marharyta KOLCHEVA (203 Česká republika), Stepan KORTUS (203 Česká republika), Karel VALES (203 Česká republika), Martin HORAK (203 Česká republika) a Ondřej SOUKUP (203 Česká republika).
Vydání European Journal of Medicinal Chemistry, PARIS, ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 2021, 0223-5234.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30107 Medicinal chemistry
Stát vydavatele Francie
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 7.088
Kód RIV RIV/00216224:14310/21:00122286
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1016/j.ejmech.2021.113434
UT WoS 000646945500020
Klíčová slova anglicky QSAR; Acetylcholinesterase; Electrophysiology; Glutamate receptor; Ion channel; Pharmacology; in vivo; Tacrine
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Michaela Hylsová, Ph.D., učo 211937. Změněno: 16. 2. 2023 12:42.
Anotace
Tacrine is a classic drug whose efficacy against neurodegenerative diseases is still shrouded in mystery. It seems that besides its inhibitory effect on cholinesterases, the clinical benefit is co-determined by NMDAR-antagonizing activity. Our previous data showed that the direct inhibitory effect of tacrine, as well as its 7-methoxy derivative (7-MEOTA), is ensured via a "foot-in-the-door" open-channel blockage, and that interestingly both tacrine and 7-MEOTA are slightly more potent at the GluN1/GluN2A receptors when compared with the GluN1/GluN2B receptors. Here, we report that in a series of 30 novel tacrine derivatives, designed for assessment of structure-activity relationship, blocking efficacy differs among different compounds and receptors using electrophysiology with HEK293 cells expressing the defined types of NMDARs. Selected compounds (4 and 5) potently inhibited both GluN1/GluN2A and GluN1/GluN2B receptors; other compounds (7 and 23) more effectively inhibited the GluN1/GluN2B receptors; or the GluN1/GluN2A receptors (21 and 28). QSAR study revealed statistically significant model for the data obtained for inhibition of GluN1/Glu2B at -60 mV expressed as IC50 values, and for relative inhibition of GluN1/Glu2A at +40 mV caused by a concentration of 100 mu M. The models can be utilized for a ligand-based virtual screening to detect potential candidates for inhibition of GluN1/Glu2A and/or GluN1/Glu2B subtypes. Using in vivo experiments in rats we observed that unlike MK-801, the tested novel compounds did not induce hyperlocomotion in open field, and also did not impair prepulse inhibition of startle response, suggesting minimal induction of psychotomimetic side effects. We conclude that tacrine derivatives are promising compounds since they are centrally available subtype-specific inhibitors of the NMDARs without detrimental behavioral side-effects.
VytisknoutZobrazeno: 31. 5. 2024 01:30